Biofrontera AG Banner Image

Biofrontera AG

  • Ticker BFRA
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Biofrontera AG Logo Image
  • 51-200 Employees
  • Based in Leverkusen, Germany
Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics. The Germany-based company, with almost 200 employees worldwide, develops and markets innovative products for the care, protection and treatment of the skin. The company's lead product is the combination of Ameluz®, a topical prescription drug, and medicalMore device BF-RhodoLED® for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz® has been marketed in the EU since 2012 and in the United States since May 2016. In addition, the company markets the prescription medication XepiTM for the treatment of impetigo in the United States. In the EU, the company also sells the dermocosmetics series Belixos®, which offers specialized care for damaged or diseased skin.
4.8 / 5.0 (107)

Biofrontera AG reports have an aggregate usefulness score of 4.8 based on 107 reviews.

Biofrontera AG

Most Recent Annual Report

Biofrontera AG
MOST RECENT 2022 Annual Report

Older/Archived Annual Reports

Biofrontera AG Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!